I met today with senior executives of seventeen of the world's research-based and generic pharmaceutical and diagnostic companies…to review progress on...expand[ing] access to HIV prevention, treatment, care and support services in low- and middle-income countries...[C]ompanies have committed individually…to: Invest further in research and development of new HIV-related medicines adapted to resource limited settings to be used safely in children, adolescents, adults and pregnant women; Invest further in developing reliable and affordable technologies to diagnose HIV and TB (among people living with HIV) and to monitor the efficacy of treatment; Enhance efforts towards urgently needed Universal Access to infant HIV diagnosis; Invest further in research and development of new biomedical HIV prevention technologies, including vaccines, microbicides and pre and post-exposure prophylaxis…[T]he UN system agreed to:…Continue to strengthen WHO prequalification programme for urgently needed essential medicines and diagnostics; Promote information sharing between the UN, national regulatory authorities and the companies in the prequalification process…Convene…technical consultations among HIV experts and between the UN and the companies on pediatric formulations and second- and third -line regimens for adults…We agreed to continuing to hold periodic high-level meetings, under the leadership of UNAIDS, to take stock of progress and to identify new collaborative measures. [Participating companies: Abbott, Aspen, Aurobindo, Becton Dickinson, bioMerieux, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Hetero, Inverness Medical Innovations, Johnson & Johnson, Matrix, Merck, Pfizer, Ranbaxy, Roche, Shanghai Kehua Bio-Engineering]